Elegance clinical trial it was reported that restenosis occurred.The subject underwent treatment with the ranger drug coated balloons on 15-jun-2022 as a part of the elegance clinical trial.The target lesion was in the right anterior tibial artery with 3.5 mm proximal reference vessel diameter and 2 mm distal reference vessel diameter with lesion length 320 mm with 100% stenosis and was classified as tasc ii c lesion.Prior to the target lesion treatment with the study device, pre-dilation was performed using 2 mm x 150 mm coyote pta balloon.Treatment of target lesion was performed by dilation using study devices, 2.5 mm x 120 mm, 3 mm x 120 mm and 3.5 mm x 150 mm ranger drug coated balloons.Following treatment, the final residual stenosis was noted to be 15%.On the (b)(6) 2022, the subject was discharged from the hospital on dual antiplatelet therapy.On 02-mar-2023, subject was noted with symptoms related to restenosis of right anterior tibial artery and was hospitalized for further evaluation and treatment.On 03-mar-2023, 261 days post index procedure, 70% stenosis noted in the right anterior tibial artery was treated with balloon dilation using coyote pta balloon.Post treatment, the final residual stenosis was noted to be 0%.On the same day, the event was considered to be resolved and on (b)(6) 2023, the subject was discharged from the hospital.
|